REVIEWS
`
`6.
`
`7.
`
`8.
`
`9.
`
`2.
`
`3.
`
`4.
`
`5.
`
`I. Schmidt, D. & Sillanpaa, M. Evidence-based review
`on the natural history of the epilepsies. Curr. Opin.
`Neurol. 25, 159-163 (2012).
`Berg, A. T. et al. Revised terminology and concepts for
`organization of seizures and epilepsies: report of the
`ILAE Commission on Classification and Terminology,
`2005-2009. Epilepsia 51, 676-685 (2010).
`Tellez-Zenteno, J. F., Patten, S. B., Jette, N.,
`Williams, J. & Wiebe, S. Psychiatric comorbidity in
`epilepsy: a population-based analysis. Epilepsia
`48, 2336-2344 (2007).
`Loscher, W. & Schmidt, D. Modern antiepileptic
`drug development has failed to deliver: ways out
`of the current dilemma. Epilepsia 52, 657-678
`(2011).
`This is the first review to show that modem AEDs
`fail to address important unmet treatment needs
`of patients with epilepsy.
`Sillanpaa, M. & Schmidt, D. Natural history of treated
`childhood-onset epilepsy: prospective, long-term
`population-based study. Brain 129, 617-624
`(2006).
`The study identified four clinically important
`seizure outcome patterns of new-onset epilepsy
`and the factors that allow their early prediction.
`Brodie, M. J .. Barry, S. J., Bamagous, G. A ..
`Norrie, J. D. & Kwan, P. Patterns of treatment
`response in newly diagnosed epilepsy. Neurology 78,
`1548-1554 (2012).
`Temkin, N. R. Preventing and treating posttraumatic
`seizures: the human experience. Epilepsia 50
`(Suppl. 2). 10-13 (2009).
`Schmidt, D. Is antiepileptogenesis a realistic goal
`in clinical trials? Concerns and new horizons.
`Epilept. Disord. 14, 105-113 (2012).
`Blumenfeld, H. et al. Early treatment suppresses the
`development of spike-wave epilepsy in a rat model.
`Epilepsia 49, 400-409 (2008).
`This is the first study to show the anti·epileptogenic
`activity of an AED in a genetic model of epilepsy.
`10. Russo, E. et al. Comparison of the antiepileptogenic
`effects of an early long-term treatment with
`ethosuximide or levetiracetam in a genetic animal
`model of absence epilepsy. Epilepsia 51 , 1560-1569
`(2010).
`11. Marson. A. G. et al. The SANAD study of effectiveness
`of carbamazepine, gabapentin, lamotrigine,
`oxcarbazepine, or topiramate for treatment of partial
`epilepsy: an unblinded randomised controlled trial.
`Lancet369, 1000-1015 (2007).
`12. Marson, A.G. et al. The SANAD study of effectiveness
`of valproate, lamotrigine, or topiramate for
`generalised and unclassifiable epilepsy: an unblinded
`randomised controlled trial. Lancet 369, 1016-1026
`(2007).
`13. Trinka, E. et al. KOMET: an unblinded, randomised,
`two parallel-group, stratified trial comparing the
`effectiveness of levetiracetam with controlled-release
`carbamazepine and extended-release sodium
`valproate as monotherapy in patients with newly
`diagnosed epilepsy. J. Neural. Neurosurg. Psychiatry
`84, 1138-1147 (2013).
`14. Brodie, M. J. et al. Enzyme induction with antiepileptic
`drugs: cause for concern? Epilepsia 54, 11-27
`(2013).
`15. Beyenburg, S., Stavem, K. & Schmidt, D.
`Placebo-corrected efficacy of modern antiepileptic
`drugs for refractory epilepsy: systematic review
`and meta-analysis. Epilepsia 51, 7-26 (2010).
`16. White, H. S .. Smith-Yockman, M., Srivastava, A.
`& Wilcox, K. S. in Models of seizures & epilepsy
`(eds Pitk~nen, A., Schwartzkroin, P.A. & Moshe, S. L.J
`539-549 (Elsevier, 2006).
`17. Bialer, M. & White, H. S. Key factors in the discovery
`and development of new antiepileptic drugs.
`Nature Rev. Drug Discov. 9, 68-82 (2010).
`18. Perucca, E., French, J. & Bialer, M. Development of
`new antiepileptic drugs: challenges, incentives, and
`recent advances. Lancet Neural. 6, 793-804 (2007).
`19. Putnam, T. J. & Merritt, H. H. Experimental
`determination of the anticonvulsant properties of
`some phenyl derivatives. Science 85, 525-526
`(1937).
`20. Toman, J. E. P., Swinyard, E. A. & Goodman, L. S.
`Properties of maximal seizures and their alteration
`by anticonvulsant drugs and other agents.
`J. Neurophysiol. 9, 231-239 (1946).
`21. Loscher, W. Critical review of current animal models
`of seizures and epilepsy used in the discovery and
`development of new antiepileptic drugs. Seizure 20,
`359-368 (2011).
`
`the first
`
`22. Everett. G. M. & Richards, R. K. Comparative
`anticonvulsive action of 3,5,5-trimethyloxazolidine-
`2,4-dione [fridione]. dilantin and phenobarbital.
`J. Pharmacol. Exp. Ther. 81, 402-407 (1944).
`23. Swinyard, E. A. Laboratory assay of clinically effective
`antiepileptic drugs. J. Am. Pharm. Assoc. 38,
`201-204 (1949).
`24. Swinyard, E. A .. Brown, W. C. & Goodman. L. S.
`Comparative assay of antiepileptic drugs in mice
`and rats. J. Pharmacol. Exp. Ther. 106, 319-330
`(1952).
`25. Barton, M. E., Klein, B. D., Wolf, H. H. & White, H. S.
`Pharmacological characterization of the 6 Hz
`psychomotor seizure model of partial epilepsy.
`Epilepsy Res. 47, 217-228 (2001).
`26. Cossart, R., Bernard, C. & Ben-Ari, Y. Multiple facets
`of GABAergic neurons and synapses: multiple fates of
`GABA signalling in epilepsies. Trends Neurosci. 28,
`108-115 (2005).
`27. Perucca, E. What clinical trial designs have been
`used to test antiepileptic drugs and do we need
`to change them? Epilept. Disord. 14, 124-131
`(2012).
`28. Friedman, D. & French, J. A. Clinical trials for
`therapeutic assessment of antiepileptic drugs in the
`21st century: obstacles and solutions. Lancet Neurol.
`11' 827-834 (2012).
`29. Krall, R. L., Penry, J. K., Kupferberg, H.J. &
`Swinyard, E. A. Antiepileptic drug development: I.
`History and a program for progress. Epilepsia 19,
`393-408 (1978).
`30. Krall, R. L., Penry, J. K., White, B. G .. Kupferberg, H.J.
`& Swinyard, E. A. Antiepileptic drug development: II.
`Anticonvulsant drug screening. Epilepsia 19, 409-428
`(1978).
`31. Klitgaard, H. & Verdru, P. Levetiracetam -
`SV2A ligand for the treatment of epilepsy.
`Expert Opin. Drug Discov. 2, 1537-1545 (2008).
`32. Srivastava, A. K. & White, H. S. Carbamazepine,
`but not valproate, displays pharmacoresistance
`in lamotrigine-resistant amygdala kindled rats.
`Epilepsy Res. 104, 2 6-34 (2O1 2).
`33. Mattson, R.H., Cramer, J. A. & Collins, J. F.
`A comparison of valproate with carbamazepine for
`the treatment of complex partial seizures and
`secondarily generalized tonic- clonic seizures in
`adults. The Department of Veterans Affairs Epilepsy
`Cooperative Study No. 264 Group. N. Engl. J. Med.
`327, 765-771 (1992).
`34. Privitera, M. D. et al. Topiramate, carbamazepine and
`valproate monotherapy: double-blind comparison in
`newly diagnosed epilepsy. Acta Neural. Scand. 107,
`165-175 (2003).
`35. Semah, F. et al. Is the underlying cause of epilepsy a
`major prognostic factor for recurrence? Neurology
`51' 1256-1262 (1998).
`36. Wheless, J. W., Clarke, D. F., Arzimanoglou, A. &
`Carpenter, D. Treatment of pediatric epilepsy:
`European expert opinion, 2007. Epilept. Disord. 9,
`353-412 (2007).
`37. Halford, J. J. et al. A randomized, double-blind,
`placebo-controlled study of the efficacy, safety, and
`tolerability of adjunctive carisbamate treatment in
`patients with partial-onset seizures. Epilepsia 52,
`816-825 (2011).
`38. Baulac, M., Leon, T .. O'Brien, T. J .. Whalen, E. &
`Barrett, J. A comparison of pregabalin, lamotrigine.
`and placebo as adjunctive therapy in patients with
`refractory partial-onset seizures. Epilepsy Res. 91 ,
`10-19 (2010).
`39. Ryvlin, P., Cucherat, M. & Rheims, S-. Risk of sudden
`unexpected death in epilepsy in patients given
`adjunctive antiepileptic treatment for refractory
`seizures: a meta-analysis of placebo-controlled
`randomised trials. LancetNeurol. 10, 961-968
`(2011).
`40. Schmidt, D., Beyenburg, S .. D'Souza, J. & Stavem, K.
`Clinical features associated with placebo response in
`refractory focal epilepsy. Epilepsy Behav. 27, 393-398
`(2013).
`41. Enck, P., Binge!, U., Schedlowski. M. & Rief, W.
`The placebo response in medicine: minimize,
`maximize or personalize? Nature Rev. Drug Discov.
`12, 191-204 (2013).
`42. Sillanpaa, M. & Schmidt, D. Early seizure frequency
`and aetiology predict long-term medical outcome in
`childhood-onset epilepsy. Brain 132, 989-998
`(2009).
`43. Schiller, Y. & Najjar, Y. Quantifying the response to
`antiepileptic drugs: effect of past treatment history.
`Neurology 70, 54-65 (2008).
`
`44. Go, C. Y. et al. Evidence-based guideline update:
`medical treatment of infantile spasms. Report of the
`Guideline Development Subcommittee of the American
`Academy of Neurology and the Practice Committee
`of the Child Neurology Society. Neurology 78,
`1974-1980 (2012).
`45. Plosker, G. L. Stiripentol: in severe myoclonic epilepsy of
`infancy (dravet syndrome). CNS Drugs 26, 993-1001
`(2012).
`46. Glauser, T. et al. Updated ILAE evidence review of
`antiepileptic drug efficacy and effectiveness as initial
`monotherapy for epileptic seizures and syndromes.
`Epilepsia 54, 551-563 (2013).
`47, Loscher, W. & Brandt, C. Prevention or modification
`of epileptogenesis after brain insults: experimental
`approaches and translational research. Pharmocol. Rev.
`62, 668-700 (2010).
`48. Pitkanen, A. & Lukasiuk, K. Mechanisms of
`epileptogenesis and potential treatment targets.
`LancetNeurol. 10, 173-186 (2011).
`49. Eastman, C. L. et al. Antiepileptic and
`antiepileptogenic performance of carisbamate after
`head injury in the rat: blind and randomized studies.
`J. Pharmacol. Exp. Ther. 336, 779-790 (2011 ].
`50. Russo, E. et al. mTOR inhibition modulates
`epileptogenesis, seizures and depressive behavior
`in a genetic rat model of absence epilepsy.
`Neuropharmacology 69, 25-36 (2013).
`51. Sloviter, R. S. & Bumanglag, A. V. Defining
`"epileptogenesis" and identifying "antiepileptogenic
`targets" in animal models of acquired temporal
`lobe epilepsy is not as simple as it might seem.
`Neuropharmacology 69, 3-15 (2012).
`52. Rogawski, M.A. & L6scher, W. The neurobiology of
`antiepileptic drugs. Nature Rev. Neurosci. 5, 553-564
`(2004).
`53. L6scher, W. & Schmidt, D. Epilepsy: perampanel -
`new promise for refractory epilepsy? Nature Rev.
`Neurol. 8, 661-662 (2012).
`54. Brodie, M. et al. Antiepileptic drug therapy: does
`mechanism of action matter? Epilepsy Behav. 21,
`490 (2011].
`55. Perucca, E. The pharmacology of new antiepileptic
`drugs: does a novel mechanism of action really
`matter? CNS Drugs 25, 907-912 (2011).
`56. Schmidt, D. Antiepileptic drug discovery: does
`mechanism of action matter? Epilepsy Behav. 21 ,
`342-343 (2011).
`57. Loeb, J. A. Identifying targets for preventing epilepsy
`using systems biology. Neurosci. Lett. 497, 205-212
`(2011).
`lnoki, K., Corradetti, M. N. & Guan, K. L.
`Dysregulation of the TSC-mTOR pathway in human
`disease. Nature Genet. 37, 19-24 (2005).
`This study describes the emerging evidence for
`a functional relationship between the mTOR
`signalling pathway and several genetic diseases.
`59. Vezzani, A. Before epilepsy unfolds: finding the
`epileptogenesis switch. Nature Med. 18, 1626-1627
`(2012).
`60. Ryther, R. C. & Wong, M. Mammalian target of
`rapamycin (mTORJ inhibition: potential for antiseizure,
`antiepileptogenic, and epileptostatic therapy.
`Curr. Neurol. Neurosci. Rep. 12, 410-418 (2012).
`61. Zeng, L. H .. Xu, L., Gutmann, D. H. & Wong, M.
`Rapamycin prevents epilepsy in a mouse model of
`tuberous sclerosis complex. Ann. Neurol. 63, 444-453
`(2008).
`This study describes the anti·epileptogenic or
`disease-modifying activity of the mTOR inhibitor
`rapamycin in a model of tuberous sclerosis,
`which stimulated clinical trials with this drug.
`62. Cohen, I., Navarro, V., Clemenceau, S .. Baulac, M.
`& Miles, R. On the origin of interictal activity in
`human temporal lobe epilepsy in vitro. Science 298,
`1418-1421 (2002).
`This important study identifies a subpopulation of
`excitatory pyramidal neurons displaying depolarizing
`GABA responses in the subicular zone of the
`hippocampus as the likely pacemaker neurons
`that initiate epileptic discharges.
`63. Loscher, W., Puskarjov, M. & Kaila, K. Cation-chloride
`cotransporters NKCC 1 and KCC2 as potential targets
`for novel antiepileptic and antiepileptogenic
`treatments. Neuropharmacology 69, 62-7 4 (2013).
`64. Dzhala, V. I. et al. NKCC 1 transporter facilitates
`seizures in the developing brain. Nature Med. 11,
`1205-1213 (2005).
`This paper provides experimental evidence
`that the NKCCl inhibitor bumetanide could be
`useful in the treatment of neonatal seizures.
`
`58.
`
`www.nature.com/reviews/drugdisc
`
`774 I OCTOBER 2013 I VOLUME 12
`
`© 2013 Macmillan Publishers Limited. All rights reserved
`
`

`
`REVIEWS
`
`65. Koyama, R. et al. GABAergic excitation after febrile
`seizures induces ectopic granule cells and adult
`epilepsy. Nature Med. 18, 1271-1278 (2012).
`This paper provides the first experimental
`evidence that bumetanide exerts an
`anti-epileptogenic effect: that is, it prevents
`the development of epilepsy after complex
`febrile seizures.
`66. Brandt, C .. Nozadze, M .. Heuchert, N., Rattka, M.
`& Loscher, W. Disease-modifying effects of
`phenobarbital and the NKCC 1 inhibitor bumetanide
`in the pilocarpine model of temporal lobe epilepsy.
`J. Neurosci. 30, 8602-8612 (2010).
`67. Eftekhari, S. et al. Bumetanide reduces seizure
`frequency in patients with temporal lobe epilepsy.
`Epilepsia 54, e9-e12 (2012).
`68. Vezzani. A., Balosso, S. & Ravizza. T. The role
`of cytokines in the pathophysiology of epilepsy.
`Brain Behav. /mmun. 22. 797-803 (2008).
`69. Vezzani, A., French, J .. Bartfai, T. & Baram, T. Z.
`The role of inflammation in epilepsy. Nature Rev.
`Neurol. 7, 31-40 (2011).
`70. Vezzani, A., Friedman, A. & Dingledine. R. J.
`The role of inflammation in epileptogenesis.
`Neuropharmacology 69, 16-24 (2013).
`71 . Vezzani, A. & Baram, T. Z. New roles for interleukin· I
`beta in the mechanisms of epilepsy. Epilepsy Curr. 7.
`45-50 (2007).
`72. Rasmussen. T., Olszewski, J. & Lloyd-Smith, D.
`Focal seizures due to chronic localized encephalitis.
`Neurology 8, 435-445 (1958).
`73. Vezzani, A .. Maroso, M .. Balosso. S .. Sanchez. M.A.
`& Bartfai, T. IL- I receptor/Toll-like receptor
`signaling in infection, inflammation. stress and
`neurodegeneration couples hyperexcitability
`and seizures. Brain Behav. lmmun. 25, 1281-1289
`(2011).
`74. Maroso, M. eta/. lnterleukin-lbeta biosynthesis
`inhibition reduces acute seizures and drug resistant
`chronic epileptic activity in mice. Neurotherapeutics
`8, 304-315 (2011).
`75. Bialer, M. et al. Progress report on new antiepileptic
`drugs: a summary of the Eleventh Eilat Conference
`(EILAT XI). Epilepsy Res. 103, 2-30 (2013).
`76. Vezzani. A. et al. Powerful anticonvulsant action of IL-1
`receptor antagonist on intracerebral injection and
`astrocytic overexpression in mice. Proc. Natl Acad.
`Sci. USA 97, 11534-11539 (2000).
`77. Vezzani, A. eta/. Functional role of inflammatory
`cytokines and antiinflammatory molecules in seizures
`and epileptogenesis. Epilepsia 43 (Suppl. 5), 30-35
`(2002).
`78. Librizzi, L., Noe. F., Vezzani, A .. De Curtis, M. &
`Ravizza. T. Seizure·induced brain·borne inflammation
`sustains seizure recurrence and blood-brain barrier
`damage. Ann. Neurol. 12, 82-90 (2012).
`This paper describes how the human recombinant
`IL-lpR antagonist anakinra terminates
`seizures, prevents their recurrence and resolves
`seizure-associated BBB breakdown in an
`animal model, supporting the use of specific
`anti-inflammatory drugs for the treatment
`of refractory seizures.
`79. Maroso, M. eta/. Toll-like receptor 4 and high-mobility
`group box-1 are involved in ictogenesis and can be
`targeted to reduce seizures. Nature Med. 16, 413-419
`(2010).
`This study indicates that TLR4 and high-mobility
`group box protein 1 contribute to the generation
`and perpetuation of epileptic activity and
`might form novel targets for the treatment
`of pharmacoresistant seizures.
`80. Fabene, P. F. et al. A role for leukocyte-endothelial
`adhesion mechanisms in epilepsy. Nature Med. 14,
`1377-1383 (2008).
`This paper proposes a novel target (factors
`involved in leukocyte-endothelial interactions,
`such as VLA4) for the prevention and treatment
`of epilepsy; VLA4 is successfully being targeted
`in the treatment of multiple sclerosis.
`81 . Fabene. P. F .. Laudanna, C. & Constantin, G.
`Leukocyte trafficking mechanisms in epilepsy.
`Mo/. lmmunol. 55, 100-104 (2013).
`82. Sotgiu, S .. Murrighile, M. R. & Constantin, G.
`Treatment of refractory epilepsy with natalizumab
`in a patient with multiple sclerosis. Case report.
`BMC Neurol. 10, 84 (2010).
`83. Friedman, A .. Kaufer, D. & Heinemann. U.
`Blood-brain barrier breakdown-inducing astrocytic
`transformation: novel targets for the prevention of
`epilepsy. Epilepsy Res. 85, 142-149 (2009).
`
`84. Shlosberg, D., Benifla, M .. Kaufer, D. & Friedman, A.
`Blood-brain barrier breakdown as a therapeutic
`target in traumatic brain injury. Nature Rev. Neurol.
`6, 393-403 (2010).
`85. Heinemann, U .. Kaufer, D. & Friedman. A.
`Blood-brain barrier dysfunction. TGFP signaling,
`and astrocyte dysfunction in epilepsy. Clio 60,
`1251-1257 (2012).
`86. Frigerio, F. et al. Long-lasting pro·ictogenic effects
`induced in vivo by rat brain exposure to serum
`albumin in the absence of concomitant pathology.
`Epi/epsia 53, 1887-1897 (2012).
`87. Cacheaux. L. P. et al. Transcriptome profiling reveals
`TGF-p signaling involvement in epileptogenesis.
`J. Neurosci. 29, 8927-8935 (2009).
`This paper identifies the TGFp pathway as a
`novel putative epileptogenic signalling cascade
`and a therapeutic target for the prevention of
`injury-induced epilepsy.
`88. Kobow, K. et al. Finding a better drug for epilepsy:
`antiepileptogenesis targets. Epilepsia 53, 1868-1876
`(2012).
`89. Roopra, A., Dingledine, R. & Hsieh, J. Epigenetics and
`epilepsy. Epilepsia 53 (Suppl. 9), 2-10 (2012).
`90. McClelland, S. et al. Neuron·restrictive silencer factor(cid:173)
`mediated hyperpolarization·activated cyclic nucleotide
`gated channelopathy in experimental temporal lobe
`epilepsy. Ann. Neural. 70, 454-464 (2011).
`91. Jimenez-Mateos, E. M. et al. Silencing microRNA-134
`produces neuroprotective and prolonged seizure(cid:173)
`suppressive effects. Nature Med. 18, 1087-1094
`(2012).
`This paper describes the upregulation of
`microRNA-134, a brain-specific, activity-regulated
`microRNA, in epileptic tissue and shows that
`silencing of microRNA-1 34 renders mice refractory
`to seizures and hippocampal injury caused by
`status epilepticus.
`92. Kobow, K. & Blumcke, I. The emerging role of DNA
`methylation in epileptogenesis. Epilepsia 53 (Suppl. 9).
`11-20 (2012).
`93. Mazzuferi, M. et al. Nrf2 defense pathway:
`experimental evidence for its protective role in
`epilepsy.Ann. Neural. http://dx.doi.org/I0.1002/
`ana.23940 (2013).
`94. Winden, K. D. et al. A systems level. functional
`genomics analysis of chronic epilepsy. PLoS ONE
`6, e20763 (2011).
`95. Kraft, A. D .. Lee, J.M., Johnson, D. A., Kan. Y. W. &
`Johnson. J. A. Neuronal sensitivity to kainic acid is
`dependent on the Nrf2-mediated actions of the
`antioxidant response element. J. Neurochem. 98,
`1852-1865 (2006).
`96. Scannevin, R. H. et al. Fumarates promote
`cytoprotection of central nervous system cells against
`oxidative stress via the nuclear factor (erythroid(cid:173)
`derived 2)-like 2 pathway. J. Pharmaco/. Exp. Ther.
`341, 274-284 (2012).
`97. Schadt, E. E. et al. An integrative genomics approach
`to infer causal associations between gene expression
`and disease. Nature Genet. 37, 710-717 (2005).
`98. Lukasiuk, K., Dabrowski, M .. Adach, A. & Pitkanen, A.
`Epileptogenesis-related genes revisited. Prog. Brain
`Res. 158, 223-241 (2006).
`99. Bertram. E. H., Zhang, D. X .. Mangan. P., Fountain, N.
`& Rempe, D. Functional anatomy of limbic epilepsy:
`a proposal for central synchronization of a diffusely
`hyperexcitable network. Epilepsy Res. 32, 194-205
`(1998).
`I 00. Engel. J. et al. Connectomics and epilepsy. Curr. Opin.
`Neurol. 26, 186-194 (2013).
`I 0 I . Wiebe, S. & Jette, N. Pharmacoresistance and the role
`of surgery in difficult to treat epilepsy. Nature Rev.
`Neural. 8, 669-677 (2012).
`I 02. Hopkins, A. L. Network pharmacology: the next
`paradigm in drug discovery. Nature Chem. Biol. 4,
`682-690 (2008).
`I 03. Ainsworth, C. Networking for new drugs. Nature Med.
`17, 1166-1168 (2011).
`I 04. Margineanu, D. G. Systems biology impact on
`antiepileptic drug discovery. Epilepsy Res. 98,
`104-115 (2012).
`I 05. LOscher, W., Rundfeldt, C. & Honack, D. Low doses of
`NMDA receptor antagonists synergistically increase
`the anticonvulsant effect of the AM PA receptor
`antagonist NBOX in the kindling model of epilepsy.
`Eur. J. Neurosci. 5, 1545-1550 (1993).
`I 06. Loscher, W. & Ebert, U. Basic mechanisms of seizure
`propagation: targets for rational drug design and
`rational polypharmacy. Epilepsy Res. Suppl. 11 ,
`17-44 (1996).
`
`I 07. Kwon, Y. S. et al. Neuroprotective and
`antiepileptogenic effects of combination of
`anti-inflammatory drugs in the immature brain.
`J. Neuroinflamm. 10, 30 (2013).
`I 08. LOscher. W. & Potschka. H. Drug resistance in brain
`diseases and the role of drug efflux transporters.
`Nature Rev. Neurosci. 6, 591-602 (2005).
`I 09. Loscher, W. & Langer, 0. Imaging of P-glycoprotein
`function and expression to elucidate mechanisms of
`pharmacoresistance in epilepsy. Curr. Top. Med. Chem.
`10, 1785-1791 (2010).
`110. Feldmann, M. & Koepp, M. P·glycoprotein imaging
`in temporal lobe epilepsy: in vivo PET experiments
`with the Pgp substrate l"C]-verapamil. Epilepsia 53
`(Suppl. 6). 60-63 (2012).
`111. Feldmann, M. et al. P-glycoprotein expression and
`function in patients with temporal lobe epilepsy:
`a case-control study. Lancet Neurol. 12, 777-785
`(2013).
`112. Autry, A. R .. Trevathan. E .. Van Naarden. B. K. &
`Yeargin-Allsopp, M. Increased risk of death among
`children with Lennox-Gastaut syndrome and infantile
`spasms. J. Child Neural. 25, 441-447 (2010).
`113. Briggs, D. E .. Lee, C. M .. Spiegel. K. & French, J. A.
`Reduction of secondarily generalized tonic-clonic
`(SGT.CJ seizures with pregabalin. Epilepsy Res. 82,
`86-92 (2008).
`114. Schmidt, D. & Loscher, W. Drug resistance in epilepsy:
`putative neurobiologic and clinical mechanisms.
`Epilepsia 46, 858-877 (2005).
`115. Remy, S. & Beck, H. Molecular and cellular
`mechanisms of pharmacoresistance in epilepsy.
`Brain 129, 18-35 (2006).
`116. Schmidt, D. & Loscher, W. New developments in
`antiepileptic drug resistance: an integrative view.
`Epilepsy Curr. 9, 47-52 (2009).
`117. Potschka, H. Role of CNS efflux drug transporters in
`antiepileptic drug delivery: overcoming CNS efflux
`drug transport. Adv. Drug De/iv. Rev. 64, 943-952
`(2012).
`118. Brandt, C .. Bethmann, K .. Gastens, A. M. &
`Loscher, W. The multidrug transporter hypothesis of
`drug resistance in epilepsy: proof-of·principle in a rat
`model of temporal lobe epilepsy. Neurobiol. Dis. 24,
`202-211 (2006).
`119. LOscher. W .. Luna-Tortos. C .. ROmermann, K. &
`Fedrowitz, M. Do ATP-binding cassette transporters
`cause pharmacoresistance in epilepsy? Problems and
`approaches in determining which antiepileptic drugs
`are affected. Curr. Pharm. Des. 17, 2808-2828
`(2011).
`120. Zhang, C .. Kwan, P .. Zuo. Z. & Baum. L. The transport
`of antiepileptic drugs by P·glycoprotein. Adv. Drug
`De/iv. Rev. 64, 930-942 (2012).
`121. Loscher, W., Klotz, U .. Zimprich, F. & Schmidt, D.
`The clinical impact of pharmacogenetics on the
`treatment of epilepsy. Epilepsia 50, 1-23 (2009).
`122. Kaminski, R. M .. Matagne. A .. Patsalos, P. N. &
`Klitgaard, H. Benefit of combination therapy in
`epilepsy: a review of the preclinical evidence with
`levetiracetam. Epilepsia 50, 387-397 (2009).
`123. Lason, W., Dudra-Jastrzebska, M., Rejdak, K. &
`Czuczwar, S. J. Basic mechanisms of antiepileptic
`drugs and their pharmacokinetidpharmacodynamic
`interactions: an update. Pharmacol. Rep. 63, 271-292
`(2011).
`124. Czuczwar, S. J. et al. Pharmacodynamic interactions
`between antiepileptic drugs: preclinical data based on
`isobolography. Expert Opin. Drug Metab. Toxicol. 5,
`131-136 (2009).
`125. Brodie, M. J. & Sills, G. J. Combining antiepileptic
`drugs -
`rational polytherapy? Seizure 20, 369-375
`(2011).
`126. Perucca, E. & Meador, K. J. Adverse effects of
`antiepileptic drugs. Acta Neurol. Scand. Suppl. 181,
`30-35 (2005).
`127. Schmidt, D. Drug treatment of epilepsy: options and
`limitations. Epilepsy Behav. 15, 56-65 (2009).
`128. Meldrum. B. Do preclinical seizure models preselect
`certain adverse effects of antiepileptic drugs. Epilepsy
`Res. 50, 33-40 (2002).
`129. Loscher, W. & Honack, D. Responses to NMDA
`receptor antagonists altered by epileptogenesis.
`TrendsPharmaco/. Sci. 12, 52 (1991).
`I 30. Loscher. W. & Schmidt, D. Strategies in antiepileptic
`drug development: is rational drug design superior to
`random screening and structural variation? Epilepsy
`Res. 17, 95-134 (1994).
`I 31. Klitgaard, H .. Matagne, A. & Lamberty, Y. Use of
`epileptic animals for adverse effect testing. Epilepsy
`Res. 50, 55-65 (2002).
`
`NATURE REVIEWS I DRUC DISCOVERY
`
`VOLUME 12 I OCTOBER 2013 I 775
`
`© 2013 Macmillan Publishers Limited. All rights reserved
`
`

`
`REVIEWS
`
`132. Bowden, C. L. & Singh, V. Lamotrigine (Lamictal JR)
`for the treatment of bipolar disorder. Expert Opin.
`Pharmacother. 13, 2565-2571 (2012).
`133. Mula, M., Kanner, A. M., Schmitz, B. & Schachter, S.
`Antiepileptic drugs and suicidality: an expert
`consensus statement from the Task Force on
`Therapeutic Strategies of the ILAE Commission
`on Neuropsychobiology. Epilepsia 54, 199-203
`(2013).
`134. Rogawski, M.A. & Loscher, W. The neurobiology of
`antiepileptic drugs for the treatment of nonepileptic
`conditions. Nature Med. 10, 685-692 (2004).
`This paper describes a concept for explaining the
`therapeutic effects of AEDs in neuropathic pain,
`bipolar disorders, migraine and other non-epileptic
`diseases.
`I 35. Bialer, M. et al. Progress report on new antiepileptic
`drugs: a summary of the Tenth Eilat Conference
`(EILAT X). Epilepsy Res. 92, 89-124 (2010).
`136. Kanner, A. M. Can neurobiological pathogenic
`mechanisms of depression facilitate the development
`of seizure disorders? Lancet Neural. 11, 1093-1102
`(2012).
`137. Rocha, L. eta/. Dopamine abnormalities in the
`neocortex of patients with temporal lobe epilepsy.
`Neurobiol. Dis. 45, 499-507 (2012).
`138. Szot, P. Common factors among Alzheimer's disease,
`Parkinson's disease, and epilepsy: possible role of the
`noradrenergic nervous system. Epilepsia 53 (Suppl. 1 ),
`61-66 (2012).
`139. Engel. J. Jr. Biomarkers in epilepsy: introduction.
`Biomark. Med. 5, 537-544 (2011).
`140. Simonato, M. et al. Finding a better drug for epilepsy:
`preclinical screening strategies and experimental trial
`design. Epilepsia 53, 1860-1867 (2012).
`141. Engel, J. Jr., Bragin, A., Staba, R. & Mody, I.
`High-frequency oscillations: what is normal and what
`is not? Epilepsia 50, 598-604 (2009).
`142. Kobeissy, F. H. et al. Leveraging biomarker platforms
`and systems biology for rehabilomics and biologics
`effectiveness research. PM & R 3, S 139-S 14 7
`(2011).
`143. Hampel, H., Lista, S. & Khachaturian, Z. S.
`Development of biomarkers to chart all Alzheimer's
`disease stages: the royal road to cutting the
`therapeutic Gordian Knot. Alzheimer.s Dement. 8,
`312-336 (2012).
`
`144. Kola, I. The state of innovation in drug development.
`Clin. Pharmacol. Ther. 83, 227-230 (2008).
`This paper describes how innovation in drug
`development necessitates the availability of
`robust and objective biomarkers for carrying
`out early proof-of-concept studies.
`I 45. Munos, B. Lessons from 60 years of pharmaceutical
`innovation. Nature Rev. Drug Discov. 8, 959-968
`(2009).
`146. Paul, S. M. et al. How to improve R&D productivity:
`the pharmaceutical industry's grand challenge.
`Nature Rev. Drug Discov. 9, 203-214 (2010).
`This is an important review on the challenges
`facing the pharmaceutical industry and how
`to address them.
`14 7. Kwan, P. et al. Definition of drug resistant epilepsy:
`consensus proposal by the ad hoc Task Force of
`the ILAE Commission on Therapeutic Strategies.
`Epilepsia 51, 1069-1077 (2010).
`I 48. Loscher. W. & Rundfeldt, C. Kindling as a model
`of drug-resistant partial epilepsy: selection of
`phenytoin-resistant and nonresistant rats.
`J. Pharmacol. Exp. Ther. 258, 483-489 (1991 ).
`This is the first paper to demonstrate that it is
`possible to select pharmacoresistant rats from
`epilepsy models and to use such animals for
`studying the mechanisms of resistance to epilepsy.
`149. Brandt, C., Volk, H. A. & Loscher, W. Striking
`differences in individual anticonvulsant response to
`phenobarbital in rats with spontaneous seizures
`after status epilepticus. Epilepsia 45, 1488-1497
`(2004).
`150. Rogawski, M.A. The intrinsic severity hypothesis of
`pharmacoresistance to antiepileptic drugs. Epi/epsia
`54 (Suppl. 2), 32-39 (2013).
`151. Leber, P. D. Hazards of inference: the active control
`investigation. Epi/epsia 30 (Suppl. 1), S57-S63
`(1989).
`152. Herman, S. t Clinical trials for prevention of
`epileptogenesis. Epilepsy Res. 68, 35-38 (2006).
`1 53. Sloviter, R. S. Progress on the issue of excitotoxic
`injury modification versus real neuroprotection:
`implications for post-traumatic epilepsy.
`Neuropharmacology 61, 1048-1050 (2011).
`154. Mani. R., Pollard, J. & Dichter. M.A. Human clinical
`trials in antiepileptogenesis. Neurosci. Lett. 497,
`251-256 (2011).
`
`155. Goddard, G. V., Mcintyre, D. C. & Leech, C. K.
`A permanent change in brain function resulting from
`daily electrical stimulation. Exp. Neural. 25, 295-330
`(1969).
`156. Ben Ari, Y., Tremblay, E., Ottersen, 0. P. & Naquet, R.
`Evidence suggesting secondary epileptogenic lesion
`after kainic acid: pre treatment with diazepam reduces
`distant but not local brain damage. Brain Res. 165,
`362-365 (1979).
`157. Vergnes, M. et al. Spontaneous paroxysmal
`electroclinical patterns in rat: a model of generalized
`non-convulsive epilepsy. Neurosci. Lett. 33, 97-101
`(1982).
`158. Cavalheiro, E. A. et al. Long-term effects of pilocarpine
`in rats: structural damage of the brain triggers
`kindling and spontaneous recurrent seizures. Epilepsia
`32, 778-782 (1991).
`159. Toman, J. E. P., Fine. E. A., Everett, G. M. &
`Henrie, L. M. Experimental psychomotor seizure
`in laboratory animals. Electroencephalogr. C/in.
`Neurophysiol. 3, 102 (1951).
`160. Loscher, W. in Models of seizures & epilepsy
`(eds Pitkanen, A., Schwartzkroin, P.A. & Moshe, S. L.)
`551-566 (Elsevier, 2006).
`161. Abou-Khalil, B. & Schmidt, D. in Handbook of Clinical
`Neurology Vol. I 08 Part I. I. (eds Stefan, H. &
`Theodore, W. H.) 723-739 (Elsevier, 2012).
`
`Acknowledgements
`The authors are very grateful to A. Vezzani, L. Kramer,
`E. Perucca and M. Rogawski for their comments and con(cid:173)
`structive criticisms on an earlier draft of the manuscript.
`
`Competing interests statement
`The authors declare .rnmpel.i.n.e..(in.110.r;.ia.U.nl.ere,s,ts: see Web
`version for details.
`
`FIJRTHER•INFORMATION
`CliniCalTrials.goy website~ htti1:/ /dfnk:ajt~iiikoOv
`NEMO Europe: http-//w.vw.nf'lmq·f11ro1~~·.<:60i
`Pr<?Ximagen· pipeline: hiiJ:!:!li!«ta):~;t,;_Q-!Mk/,~.~.i~:i.ir.;!dP.iP.!:'.llJ1!<1
`US .f~od and Drug Administration •9!Jidance. fo~ Industry'
`doCUment (E 10 Choice ofCOntrol qroyf>:arid Related Issues
`Jn Cllnlccll Trials): hU:r>.M'h\<Y.6•i.,fd.t!;.$.l.~~Y:/.Q9..wnfaA~b/J~i.yhfoJJ~.Q~/
`P\:.M!lDJJ.9.fXlf
`ALL LINKS ARE ACTIVE IN THE ONLINE PDF
`
`776 I OCTOBER 2013 I VOLUME 12
`
`www.nature.com/reviews/drugdisc
`
`© 2013 Macmillan Publishers Limited. All rights reserved